Processing of tumor tissues for vaccination with autologous tumor cells

European Surgical Research

Volumn 29, Issue 4, 1997, Pages 292-302

  Lahn, M ^a   Kohler G ^b   Schmoor, C ^f   Dengler, W ^a   Veelken, H ^a   Brennscheidt, U ^a   Mackensen, A ^a   Kulmburg, P ^a   Hentrich, I ^a   Jesuiter, H ^a   Rosenthal, F M ^a   Fiebig, H H ^a   Sommerkamp, H ^c   Farthmann, E H ^d   Hasse, J ^e   Mertelsmann, R ^a   Lindemann, A ^a  

^a Hämatologie Onkologie   (Germany)

^b Allgemeine Pathologie   (Germany)

^c Abteilung Urologie   (Germany)

^d Allgemeine Chirurgie und   (Germany)

^e Lungenchirurgie und   (Germany)

^f UNIVERSITY OF FREIBURG   (Germany)

Author keywords

Biopsy; Cell culture; Processing; Tumor; Vaccination

Indexed keywords

TUMOR ANTIGEN;

ARTICLE; CANCER IMMUNOTHERAPY; CELL STRUCTURE; CELL SUSPENSION; COLON CARCINOMA; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; KIDNEY CARCINOMA; LUNG NON SMALL CELL CANCER; MELANOMA; PRIORITY JOURNAL; TUMOR BIOPSY; TUMOR CELL CULTURE; TUMOR VASCULARIZATION; VACCINATION;

EID: 8544283019     PISSN: 0014312X     EISSN: 14219921     Source Type: Journal    
DOI: 10.1159/000129536     Document Type: Article

References (25)

1. Boon T, Le Placnh, Lurquin C, Van den Eyndc B, Van der Bruggcn I, Traversan T, Amur-Costcsec A, Van Pel A: Identification of tumor rejection antigens recognized by T lymphocytes: in McMtchael AJ. Bodmer WF (eds):New Look at Tumour Immunology. Cancer Sut-vcys New York. Cold Spring Harbor Laboratory Press, 1992. vol 13.PP.23-37
2. Mackensen A, Fcrradini I, Carce-lain J. Tricbcl F, Faurc F, Viel S, Herccnd T: Evidence for in situ amplification of cytotoxic T lympho-cytcs with antitumor activity in a human regressive melanoma Cancer Res 1993:53:3569-3573.
3. Bcrd D, Maguire IIC, Masterngclo MJ: Introduction of cdl-mediated immunity to autologous melanoma cells and regression of metaxuses after treatment with u mclanoaia cell vaccine preceded by cyclophosphamide. Cancer Res 1986:46:2572-2575.
4. Purdoll D: Cancel vaccines. Immunol Today 1993:14:310-316.
5. Jaffe EM, Dranoff G, Cohen LK, Hauda KM, Clift S, Marshall FF, Mulligan RC, Pardoll DM: High efficiency gene transfer into primary human tumor explants without cell selection. Cancer Res 1993:53: 2221-2226.
6. Lindemann A, Brossart P, Hoffkcn K, Flasshove M, Voliotis D, Diehl V, Heckcr G, Wagner H, Mertels-mann R: Immunomodulatory effects of ultra-low-dose interleukin-2 in cancer patients: A phase-IB study. Cancer Immunol Immunother 1993;37:307-315.
7. Rosenthal FM, Cronin K, Bannerji R, Golde DW, Gansbacher B: Augmentation of antitumor immunity by tumor cells transfected with a retroviral vector carrying the inter-lcukin-2 and interferon-'/cDNAs. Blood 1994;83:1289-1298.
8. Van dcr Bruggen P, Traversari C, Chomez P, Lurquin C, De Plaen E, Van den Eynde B, Knuth A, Boon T: A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 1991; 254:1643-1647.
9. Fearon ER, Pardoll DM, Itaya T, Golumbek P, Levitsky HI, Simons JW, Karasuyama H, Vogelstcin B, Frost P: Intcrlcukin-2 production by tumor cells bypasses T helper function in the generation of an antitumor response. Cell 1990;60:397-403.
10. Gansbacher B, Zier K, Daniels B, Cronin K, Bannerji R, Gilboa E: Interleukin 2 gene transfer into tumor cells abrogates tumorigenicity and induces protective immunity. J Exp Med 1990;172:1217-1224.
11. Golumbek P, Lazenby AJ, Levitsky HI, Jaffcc LM, Karasuyama H, Baker M, Pardoll DM: Treatment of established renal cancer by tumor cells engineered to secrete interleu-kin-4. Science 1991;254:713-716.
12. Patel PM, Flemming CL, Fisher C, Porter CD, Thomas JM, Gore ME, Collins MKL: Generation of inter-leukin-2-sccreting melanoma cell populations from resected metastatic tumors. Hum Gene Ther 1994;5: 577-584.
13. Rosai J: Gross techniques in surgical pathology; in Stamathis G (ed): Ackerman's Surgical Pathology, ed 7. St. Louis, Mosby Company, 1989, vol 1, pp 13-29.
14. Doyle A, Morris CB: Cryopreserva-tion; in Doyle A, Griffiths JB, Newell DG (eds): Cell and Tissue Culture: Laboratory Procedures. 4C. Core Techniques. London, Wiley, 1993, vol 1/4C, pp 1.2-1.3.
15. Wissenschaftliche Tabellen Geigy, Teilband Statistik, ed 8. Basel, Ciba Geigy, 1988.
16. Altman DG: Practical statistics for medical research. London, Chapman Hall, 1991.
17. Veelken H, Mackcnsen A, Lahn M, Kohler G, Becker D, Franke B, Brennscheidt U, Kulmburg P, Rosenthal FM, Keller H, Hasse J, Schultze-Sccmann W, Farthmann EH, Mertelsmann R, Lindemann A: A phase I clinical study of autologous tumor cells plus intcrlcukin-2-gcne-transfected allogeneic fibroblasts as a vaccine in patients with cancer. Int J Cancer 1996,70:269-277.
18. Berger DP, Winterhalter BR, Ficbig HH: Establishment and characterization of human tumor xenografts in thymus-aplastic nude mice; in Fiebig HH, Berger DP (eds): Im-mundeficient Mice in Oncology. Contrib Oncol. Basel, Karger, 1992, vol 42, pp 23-46.
19. Berger DP, Fiebig HH, Navarro-Liickel IC, Hiddemann W, Licht T, Winterhalter BR, Leder GH, Lohr GW: Development of cell lines from human tumor xenografts growing subcutaneously in nude mice. Blut 1989:59:321.
20. Bacchi CE, Bonetti F, Pea M, Mar-tignoni G, Gown AM: HMB-45 - a review. Appl Immunohistochem 1996;4:73-85.
21. Fernando SS, Johnson S, Bate J: Im-munohistochcmical analysis of cutaneous malignant melanoma: Comparison of S-100 protein, HMB-45 monoclonal antibody and NKI/C3 monoclonal antibody. Pathology 1994;26:16-19.
22. Vessierc-Louveaux F, Darville M, Knuth A, Boon T: Use of irradiated mouse fibroblasts to improve the cloning and adaptation to culture of human melanoma cells. Int J Cancer 1985;35:231-235.
23. Dillman RO, Nayak SK, Beutel L: Establishing in vitro cultures of autologous tumor cells for use in active specific immunotherapy. J Immunother 1993;14:65-69.
24. Lewko WM, Ladd P, Hubbard D: Tumor acquisition, propagation, and preservation. Cancer 1989;64: 1600-1607.
25. Stevenson H, Gazdar AF, Phelps R: Tumor cell lines established in vitro: An independent prognostic factor for survival in non-small-cell lung cancer. Ann Intern Med 1990; 113: 764-770.